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Abstract: 
Celiac disease (CD) is gluten induced enteropathy which requires jejunal biopsy for diagnosis. To select the patients for 
endoscopoic procedure some serologic tests are popular in clinical practice for screening of CD. Although gliadin is one of the key 
immuno activator of the disease; serological screening by immuno-detection of gliadin is not recommended.  In this context we 
have designed a peptide using tools of computational biology keeping molecular pathogenesis of the disease into consideration 
such that antigliadin antibody detection based sensitive and specific cost effective tool for screening of celiac disease can be 
developed. The designed peptide QPFPEP interacts in a stable manner with dimeric immunoglobin A1 molecule and its parent 
peptide QPFPQP are sequentially present in maximum number of gliadin epitopes.   This hexapeptide is predicted to interact with 
dimeric IgA1, which increases in the biofluids of the CD patients. 
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Background: 
Celiac disease (CD) is a chronic illness which is  characterized 
by mucosal lesion  of the  small intestine and  impaired   
nutrient  absorption by the bowel that  improves  on gluten  
free diet. Its diagnosis is based on demonstration of villous 
atrophy in jejunal mucosa. The jejunal tissue is generally 
obtained by endoscopoic biopsy, which is an invasive 
procedure. To select the subjects for invasive jejunal tissue 
biopsy there exist a handful of serologic screening test that are 
commonly used in routine clinical practice [1]. In CD the role 
of tissue transglutaminase (TTG) and gliadin is proved beyond 
any doubt. The disease involves antibody formation against 
both of these proteins. Diet containing gluten supplies gliadin, 
a glutamine rich protein to the intestine. The elevated level of 
activated TTG in CD deamidate gliadin and Immunoglobulin 
A (IgA) antibody is generated against both TTG and gliadin, 
which are used for serologic screening of the disease [2]. 
Gliadin is recognized as one of the key immune activator in 
CD [3]. Although gliadin is a key pathogenic molecule of CD, 
serum IgA antigliadin antibody (IgA AGA) is not observed to 
be always an efficient tool for screening of CD. Some studies 
advocate its good sensitivity and specificity for such screening 
purpose [4], while other studies express an opposite view [5]. 
Currently no authority is advocating the use of serum IgA BIOINFORMATION  open access 
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AGA as a screening tool for CD [6]. Similar is the case with the 
status of salivary IgA AGA estimation for CD. Some studies 
demonstrate positive result for the purpose and others exhibit 
the opposite [7]. Contrary to IgA AGA estimation, in both 
serum and saliva IgA TTG seems to be promising for the 
purpose of screening for CD [8]. The reason for such disparity 
of immuno-elevation of IgA-AGA and IgA-TTG in CD is 
currently not understood. 
 
Some aspects are often ignored in the immunodetection of IgA-
AGA in the context of CD. For immunodetection of IgA-AGA, 
generally gliadin antigen is immobilized in a well over which 
the sample is applied and that follows addition of secondary 
labeled antibody. It is supposed that gliadin antigen will react 
with sample IgA antigliadin antibody [9]. In this modality of 
immunodetection, a CD specific fundamental change of gliadin 
molecule is ignored. In CD tissue trans-glutaminase acts on 
glutamine residues of gliadin and convert it to glutamate. 
Tissue trans-glutaminase is significantly elevated in CD and it 
is known to cause deamidation of gliadin molecule and this 
altered gliadin molecule evokes immune response in CD [8]. 
Therefore it is quite possible that the generated IgA antigliadin 
antibody will better react with the altered gliadin with 
glutamine residues changed to glutamate. Recently it is proved 
beyond any doubt that IgA raised against deamidated gliadin 
is superior for the diagnosis/screening of celiac disease [10]. 
Supporting this view there is evidence that two stretches of 
nonapeptides derived from gliadins with glutamine changed 
to glutamate interact well with sera of CD patients,however 
the number of amino acids that binds with antibody can be 
even less than nine [11]. For practical reason, involvement of 
peptides in a diagnostic test with more number of amino acids 
will increase the cost of the analysis. Keeping this fundamental 
inappropriateness we have designed a shorter peptide using 
tools of computational biology that may be experimentally 
verified for the purpose. The designed peptide is supposed to 
overcome the current limitations of IgA antigliadin antibody 
estimation in bio -fluids of CD patients and if found 
satisfactory after experimental validation is expected to reduce 
the current cost of the deamidated peptide based diagnosis of 
CD. 
 
Methodology: 
Modeling of the 3-Dimesional structure of IgA 
Carbon alpha co-ordinates of dimeric immunoglobin A1 is 
retrieved (PDB code 2QTJ) from protein data bank [12]. The 
three dimensional structure is modeled using SABBAC tool 
[13] and is used for analyzing peptide-IgA interaction. 
 
Peptide designing 
It has been found from the literature that N-terminal region of 
gladin protein has the epitope binding site and have high 
content of PQ [14]. The sequence of gliadin has been taken 
from NCBI [15] and performed the BLAST [16] search against 
the non-redundant database. Four motifs rich in proline and 
glutamine which are found are given below and in parenthesis 
the number of hits of the consensus sequence is mentioned.  
1) QLQPFPQP (71 hits); 2) QFPQ (70 hits); 3) QLQPFPQPFPP 
(no hits); 4) QPFPQPFPP (no hits). Similar procedure has been 
applied for hordein and secalin present in barley and rye 
respectively, which are homologous to gliadin and also 
responsible for CD [17]. 1) QPYPQ (30 hits); 2) 
QPQPYPQQPFPP (6 hits); 3) QPYPQQPFPP (9 hits). After 
combining these outputs, we have designed 16 peptide 
sequences (that may bind to IgA in both monomeric and 
dimeric forms) as follows: 
1) QLQPFPQP; 2) QLQPYPQP; 3) QPFPQ; 4) QPYPQ; 5) 
QLQPFP; 6) QPQPFP; 7) QQQPFP 8) QPQPFPQ; 9)QPQPYPQ; 
10)  QPFPQQPFPP; 11) QPYPQQPFPP; 12) QPFPQP; 13) 
QPYPQP; 14) QQQPYP; 15) QGSFQP; 16) QGFFQP 
 
These peptides have been designed in extended conformation 
using pymol [18] and then energy is minimized using swiss 
pdb viewer [19] generating two different sets of minimized 
and non-minimized conformations. 
 
Docking 
The peptides are docked using AutoDock4.0 [20]. Each peptide 
is docked against monomeric IgA at epitope binding region of 
Fab for first monomer, taking the grid center as the center of 
Fab region consisting of L and A chain and extends point upto 
62 in each direction of X, Y and Z axis. Ten best conformations 
of peptide-IgA complexes are taken into consideration. The 
number of cases have been manually checked and counted 
where the peptide is present at variable and junction of 
variable-constant region of IgA and given in Table 1. Out of 
them, those are found at variable and junction of variable-
constant region in higher number of cases are taken for further 
docking and thus seven peptides have been selected which are 
given in bold letters in Table 1. Then, the grid centre is taken 
on residue Tyr33 of chain A (because this residue is the 
approximate centre of the Fab variable region having L and A 
chains) and selected peptides have been docked against IgA 
monomer consisting of L and A chains.  
 
The best fit peptide is docked at the second epitope binding 
region of the first monomer having M and B chains with grid 
centre Arg45 of B chain (because this residue is the mirror 
image of the Tyr33 and hence the approximate center of Fab 
variable region having M and B chains). Afterwards, to see its 
interaction in the dimeric form it is also docked at the other 
monomer at their respective epitope binding sites. 
 
Result and Discussion 
Docking and Analysis of gluten peptides with IgA 
First of all, 16 peptides as mentioned in methods have been 
designed to check the binding with IgA. Two sets of these 
peptides have been made: one having the non-minimized 
conformation and the second one having the minimized 
conformation using swiss pdb viewer energy minimization 
tool. However two peptides, QGSFQP and QGFFQP have been 
rejected because no poly-proline are present in the sequences 
which is the main characteristic and requirement of gluten 
peptide to bind with IgA [14].  So, 14 peptides have been 
selected for docking with Autodock with grid centre at the 
centre of the Fab region. The number of cases where these 
peptides (both minimized and non-minimized conformations) 
are observed at variable and junction regions of IgA are 
summarized in Table 1 (see supplementary material). Peptide 
QPFPQP is interacting with better orientation than QPYPQP 
with IgA as QPYPQP is shifted more towards the junction 
region while QPFPQP is interacting at the variable region. 
Thus 7 peptides which are found in higher numbers at these 
regions have been selected for further docking with grid centre BIOINFORMATION  open access 
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at Tyr33 position (because Tyr33 is the approximate center of 
the Fab variable region) and are given in bold letter in Table 1. 
Though the peptide QPFPQQPFPP is tightly fitted in the IgA 
molecule, only 1 or 2 residues are actually interacting with IgA 
and rest are away from it because of the orientation of the 
peptide is outwards. Peptide QPFPQ is weakly interacting 
with IgA because it is in the vicinity of the IgA molecule and 
the distance is also more.  However, by addition of a Proline 
residue at the C terminus of peptide QPFPQ, there is a drastic 
improvement in the binding of the peptide with IgA. The 
p e p t i d e  Q P F P Q P  i s  p r o p e r l y  f i t t e d  a t  t h e  v a r i a b l e  r e g i o n  o f  
IgA, all residues are interacting with Fab region, side chains of 
the IgA molecule are also visible to be interacting with the 
peptide and the orientation is also accurate. Remaining 4 
peptides in bold letter of Table 1 are also interacting with IgA 
molecule at variable region. But the peptide QPFPQP is 
interacting better than all of the other peptides. 
  
So, the peptide QPFPQP is selected as the best peptide and is 
docked with the two monomeric and dimeric forms of the IgA 
molecule. The peptide QPFPQP is interacting at both the lobes 
of Fab region in the first monomer having L, M, A and B 
chains. Similarly the peptide is also docked with the other 
monomer having N O, C and D chains and is found to interact 
with variable region of IgA. Finally, the peptide is docked with 
the dimeric IgA molecule and is properly interacting at all the 
four lobes of Fab variable region. 
 
Interaction between best fit peptide and IgA molecule 
 
 
Figure 1: Interactions between the residues of peptide QPFPQP 
(in 1a), QPFPEP (in 1b), EPFPQP (in 1c) and EPFPEP (in 1D) 
with IgA molecule are shown in ball and stick mode. Green 
and magenta color shows the residues of IgA molecule which 
are interacting while white color shows the peptides with 
oxygen and nitrogen atoms in red and blue color, respectively. 
The black dashed lines indicate atoms which are in contact 
with distance (in Å). The interacting residues are labeled with 
one letter amino acid code followed by residue number and 
chain id. 
 
The interactions between peptides and IgA molecule are 
represented in Figure 1. Two Gln residues of the peptide may 
form hydrogen bonds with polar residue Y33A and acidic 
residue E55A of IgA molecule as the interacting bond distances 
between hydroxyl and amino groups are 2.6 and 2.7v 
respectively (Figure 1a). If Q5 is substituted by E the chance of 
more number of hydrogen bond formation increases; thereby 
increasing the stability (Figure 1b). However substitution of 
either Q1 or both Q1 and Q5 decreases the chance of hydrogen 
bond formation (Figure 1c, d). It is expected that QPFPEP will 
intreact with the homo-dimeric IgA molecule in a similar 
fashion as it interacts with monomeric IgA molecule and more 
strongly than QPFPQP. At the variable region of IgG molecule 
(PDB code 7FAB) QPFPQP can bind weakly but QPFPEP 
cannot bind (data not shown). 
 
The results presented clearly demonstrate that the designed 
peptide QPFPEP interacts in a stable manner with dimeric 
immunoglobin A1 molecule and its parent peptide QPFPQP is 
sequentially present in maximum number of gliadin epitopes.  
The interaction is specific for IgA AGA detection as the 
peptide does not even interact with IgG. In the designed 
hexapeptide chance of nonspecific hydrophobic interaction is 
less as it contains only one hydrophobic residue (F). The 
peptide is derived from deamidation of QPFPQP, a gliadin 
derived peptide and therefore in derivation of the designed 
peptide, the CD specific change of gliadin is kept into 
consideration. Earlier phage display study have emphasized 
role of PEQ for epitope binding [11]. Here, if the last amino 
acid of the designed peptide is changed from P to Q our 
designed peptide will have PEQ tripeptide sequence. But in 
this mode of peptide engineering it will loose poly-proline, 
presence of which is proved to be biologically important for 
gliadin in the context of pathogenesis of CD [14]. Therefore we 
advocate QPFPEP sequence to be tried for the purpose. 
 
Conclusion: 
The hexapeptide (QPFPEP) predicted to bind specifically with 
IgA antigliadin antibody. If it is proved to be a fact by 
experimental analysis the hexapeptide has the potential to 
provide a cost effective method for screening of celiac disease.  
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Supplementry material: 
 
Table 1: Table showing the number of cases where minimized and nonminimized conformations of the peptides are located at the 
variable and junction regions of IgA out of ten peptide-IgA complexes for each conformation of peptide obtained by using the center 
of the Fab region as the grid center for docking. The peptides in bold-letter are found in higher number of cases at variable and 
junction regions compared to rest of the peptides. 
 
 
S.No. 
 
 
Peptides 
                                                                     Number of cases 
Minimized conformation of peptide (Out of 10 
peptide-IgA complex) 
Nonminimized conformation of peptide (Out of 10 
peptide-IgA complex) 
Variable Region of IgA  Junction Region of IgA  Variable Region of IgA  Junction Region of IgA 
1 QLQPFPQP  0  0  1  1 
2 QLQPYPQP  0  0  0  0 
3  QPFPQ  2 2  1  2 
4  QPYPQ  3 0  2  3 
5  QLQPFP  0 0  3  1 
6 QPQPFP  0  1  1  1 
7  QQQPFP  1 0  2  1 
8 QPQPFPQ 0  0  0  1 
9 QPQPYPQ 1  0  0  0 
10 QPFPQQPFPP  0  0  0  0 
11  QPYQQPFPP  3 0  0  0 
12  QPFPQP  3 0  3  1 
13  QPYPQP  1 1  1  1 
14 QQQPYP  0  0  0  0 
 
 